INTRODUCTION
The risk of venous thromboembolism (VTE) is up to 50-fold higher in patients with cancer compared with those without [1] The incidence of VTE ranges from 3 to 15% per year in cancer patients [1] . Gastric cancer, pancreatic cancer, and multiple myeloma are associated with the highest rates of VTE, followed by lung, colorectal, and gynecological cancer [2] [3] [4] . Several cancer treatments even further increase the risk of VTE in both solid and hematological malignancies [5] [6] [7] .
In cancer patients, the treatment of VTE is challenging because the risks of both recurrent VTE and bleeding are higher than in those without cancer [8] . Several knowledge gaps limit our understanding of the benefit-risk trade-off of anticoagulation treatment between recurrence of VTE and bleeding in patients with different types of cancer. In addition, the relative efficacy and safety of direct oral anticoagulants and low-molecular-weight heparins for treatment of VTE in these subgroups have not been previously evaluated. Increasingly, oncologists specialize in certain cancer types, and, therefore, data per cancer type may be welcome for decision-making.
The Hokusai VTE Cancer study randomly assigned 1,050 patients with solid or hematological malignancies who had symptomatic or incidentally detected pulmonary embolism (PE) or proximal deep vein thrombosis (DVT) to oral edoxaban or subcutaneous dalteparin [9] . Non-inferiority of edoxaban was demonstrated for the primary outcome, which was the composite of recurrent VTE or major bleeding. This study provides an opportunity to address the knowledge gaps identified above. In the current analysis, we report on the risks of recurrent VTE and major bleeding in the largest groups of cancer patients enrolled in the Hokusai VTE Cancer study, including patients with gastrointestinal, lung, urogenital, breast, hematological, and gynecological cancer. This report extends the data presented in the main manuscript by presenting (1) clinical outcomes for cancer types not addressed in the main manuscript, (2) subgroups defined by adjudicated cancer diagnosis data, (3) detailed patient characteristics for each subgroup, (4) results for both the 6-and 12-month follow-up period, and (5) absolute risk differences between treatment groups. These additional data are helpful for translating the overall study results to clinical practice.
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METHODS

Design of the Hokusai VTE Cancer study
The rationale, design, and results of the randomized, open-label, Hokusai VTE Cancer study have been reported previously [9, 10] . Briefly, adult patients with active cancer and acute symptomatic or incidentally detected proximal DVT and/or PE were randomly allocated to treatment with either edoxaban 60 mg once daily (or 30 mg in those meeting criteria for dose reduction) after a low-molecular-weight heparin lead-in of at least 5 days, or to dalteparin. The dosage of dalteparin was 200 IU per kg for the first month, followed by a reduced dose of 150 IU per kg thereafter. The minimum required treatment duration was 6 months, after which continuation up to 12 months was advised but left at the judgment of the treating clinician. The patient flow diagram and full in-and exclusion criteria are shown in Supplementary Figure 1 and Supplementary Table  1 , respectively. All patients provided written informed consent and the study was approved by the ethical committees of participating centers.
Subgroups
For this analysis, the efficacy and safety of edoxaban were evaluated in subgroups of patients with gastrointestinal, lung, urogenital, breast, hematological, and gynecological cancer. To classify patients in cancer subgroups, adjudicated cancer diagnosis data were used, based on the assessment of a physician who was unaware of the patient's treatment assignment. As a result, numbers in subgroups differ from that of the previous reported results, which were based on non-adjudicated data provided by the study physicians [9] . Definitions used for the various cancer types are listed in Supplementary Table 2 .
Outcomes
The primary outcome was the composite of adjudicated first recurrent VTE or major bleeding. Secondary outcomes were recurrent VTE and on-treatment major bleeding separately. Recurrent VTE was defined as a new diagnosis of symptomatic or incidental DVT or PE or fatal PE including unexplained death for which PE could not be ruled out. The definition of major bleeding was in accordance with the criteria of the International Society on Thrombosis and Haemostasis [11] . An independent clinical events committee, unaware of treatment allocation, adjudicated all suspected outcomes, causes of death and the severity of clinical presentation of major bleeding events.
Statistical analysis
All outcomes were evaluated over the complete 12-month study period. As in the main study, a sensitivity analysis restricted to the first 6 months of follow-up was performed. The primary outcome and recurrent VTE were both analyzed in the modified intention-to-treat population, which consisted of patients who were randomized and received at least one dose of study drug. The analysis of major bleeding was performed in the safety population on-treatment, which only included bleeding events occurring while receiving the assigned study drug or up to 3 days after the last dose.
Risk differences were presented with 95% confidence intervals calculated using Wald's asymptotic method with Yates continuity correction in case an expected cell count was lower than 5. Between-group differences were assessed with Chi-square tests for categorical variables and one-way ANOVA for continuous variables. Kaplan-Meier curves were constructed to show the cumulative incidence of the primary outcome within each subgroup. Statistical analyses were performed in R, version 3.5.1 (The R Project for Statistical Computing, www.R-project.org).
RESULTS
Overall study population
Of 1,050 patients enrolled, 1,046 were included in the modified intention-totreat analysis. The type of cancer was gastrointestinal in 305 patients (29%), lung in 152 (15%), urogenital in 138 (13%), breast in 125 (12%), hematological in 111 (11%), and gynecological in 111 (11%). Baseline characteristics for the complete study group and for patients with various types of cancer are shown in Supplementary Table 3 and Table 1 , respectively. The median treatment duration with edoxaban was 211 days compared with 184 days with dalteparin (P=0.01). During the 12-month study period, the combined outcome of recurrent VTE or major bleeding occurred in 67 of 522 patients given edoxaban (12.8%) and in 71 of 524 patients (13.5%) given dalteparin (hazard ratio [HR], 0.97; 95% CI, 0.70 to 1.36; P=0.006 for non-inferiority).
Gastrointestinal cancer
The Table 3 ). The mean age in this group was 64.0 years and 66.2% were female. The majority had distant metastasis (67.5%) and received cancer treatment in the 4 weeks before randomization (71.5%) ( Table 1) .
During the 12-month study period, the primary outcome occurred in 32 of 165 (19.4%) patients with gastrointestinal cancer allocated to edoxaban and in 21 of 140 (15.0%) allocated to dalteparin (risk difference, 4.4%; 95% CI, -4.1% to 12.8%; Table 2 ; Figure 1A ). Recurrent VTE occurred in 16 (9.7%) patients treated with edoxaban and in 19 (13.6%) treated with dalteparin (risk difference, -3.9%; 95% CI, -11.1% to 3.4%, Supplementary Figure 2 ). The risk of on-treatment major bleeding was higher in the edoxaban group (n=21; 12.7%) than in the dalteparin group (n=5; 3.6%; risk difference, 9.2%; 95% CI, 3.2 to 15.1, Supplementary Figure 3 ). Most of these bleeding events occurred in the gastrointestinal tract (n=19; 91%), of which 9 (47%) were classified as upper gastrointestinal bleeds. The sensitivity analysis restricted to the first 6 months showed a similar pattern ( Table 2) .
Results were consistent in patients with luminal gastrointestinal cancers (i.e. esophageal, gastric, or colorectal cancer), in which the primary outcome in the 12-month study period occurred in 11 of 49 (22.5%) patients receiving edoxaban, and in 7 of 40 patients receiving dalteparin (17.5%; risk difference, 4.9%; 95% CI, -11.6 to 21.5). The risk of recurrent VTE in this period was numerically lower in the edoxaban group (n=5; 10.2%) than in the dalteparin group (n=7; 17.5%, risk difference, -7.3%; 95% CI, -21.8 to 7.2). The risk of on-treatment major bleeding was numerically higher in those receiving edoxaban (n=7; 14.3%) than in those receiving dalteparin (n=2; 5%, risk difference, 9.3%; 95% CI, -4.9 to 23.5). Outcomes for individual types of gastrointestinal cancer for the 6-and 12-month period are presented in Supplementary Tables 4 and 5, respectively.
Lung cancer
Of the 152 patients with lung cancer, 58% were male and the mean age was 65.6 years ( Table 1) . Distant metastasis was present in 71.7% of patients and 66.5% received cancer treatment. One hundred thirty-six patients (89.5%) had non-small cell lung cancer, 14 (9.2%) small cell lung cancer, 1 (0.7%) carcinoid, and 1 (0.7%) lung cancer of unknown origin.
During the 12-month study period, the primary outcome occurred in 8 of 77 (10.4%) lung cancer patients treated with edoxaban and in 8 of 75 (10.7%) treated with dalteparin (risk difference, -0.3%; 95% CI, -10.0% to 9.5%; Table 2; Figure  1B) . Recurrent VTE occurred in 7 patients (9.1%) allocated to edoxaban and in 8 (10.7%) allocated to dalteparin (risk difference -1.6%; 95% CI,-11.1% to 7.9%, Supplementary Figure 2 ). On-treatment major bleeding occurred in 2 patients (2.6%) receiving edoxaban and in none receiving dalteparin (risk difference, 2.6%; 95% CI, -2.3% to 7.5%, Supplementary Figure 3 ). None of the major bleeding events was of pulmonary origin. The sensitivity analysis restricted to the first 6 months yielded comparable results ( Table 2) . Outcomes for individual types of lung cancer for the 6-and 12-month period are presented in Supplementary Tables 4 and 5, respectively.
Urogenital cancer
Of the 138 patients with urogenital cancer, 62 (44.9%) had prostate cancer, 30 (21.7%) bladder cancer, 26 (21.7%) renal cancer, 15 (10.9%) testicular cancer, and 5 (3.6%) other types of urogenital cancer ( Table 1 ). The mean age was 65.0 years and most patients were male (90.9%). Distant metastasis was present in 60.1% and 65.9% of patients were receiving cancer treatment.
During the 12-month study period, the primary outcome occurred in 9 of 66 (13.6%) patients treated with edoxaban and in 9 of 72 (12.5%) treated with dalteparin (risk difference, 1.1%; 95% CI, -10.1% to 12.4%; Table 2 ; Figure 1C ). Recurrent VTE occurred in 6 patients (9.1%) treated with edoxaban and in 8 (11.1%) treated with dalteparin (risk difference, -2.0%; 95% CI,-12.1% to 8.0%, Supplementary Figure 2 ). On-treatment major bleeding occurred in 3 (4.6%) patients in the edoxaban group and in 1 (1.4%) in the dalteparin group (risk difference, 3.2%; 95% CI,-4.0% to 10.3%, Supplementary Figure 3 ). Of these bleeding events, 1 was located in the urogenital tract in the edoxaban group. The sensitivity analysis focusing on events that occurred during the first 6-months showed a comparable distribution over the treatment groups ( Table 2) . Outcomes for individual types of urogenital cancer for the 6-and 12-month period are presented in Supplementary Tables 4 and 5, respectively.
Breast cancer
Breast cancer was the primary diagnosis in 125 study patients, of which 120 (96.0%) were female. The mean age was 63.1 years and 89.5% received cancer treatment.
During the 12-month study period, the primary outcome occurred in 2 of 65 (3.1%) patients receiving edoxaban and in 7 of 60 (11.7%) receiving dalteparin (risk difference, -8.6%; 95% CI, -19.3% to 2.2%; Table 2; Figure 1D ). Recurrent VTE occurred in 2 patients (3.1%) in the edoxaban group and in 3 (5.0%) in the dalteparin group (risk difference, -5.3%; 95% CI, -15.0% to 4.5%, Supplementary  Figure 2 ). On-treatment major bleeding occurred in none of the patients treated with edoxaban and in 2 patients treated with dalteparin (3.3%) over 12 months (risk difference, -5.3%; 95% CI, -9.5% to 2.8%, Supplementary Figure 3) . The sensitivity analysis of events that occurred during the first 6-months showed comparable results ( Table 2) .
Hematological malignancy
Of the 111 patients with a hematological malignancy, 44 (39.6%) had lymphoma, 40 (36.0%) multiple myeloma, 19 (17.1%) leukemia, and 8 (7.2%) other types of hematological malignancies. The mean age was 65.2 years, 62.2% were male and 77.5% of patients were receiving cancer treatment.
During the 12-month study period, the primary outcome occurred in 5 of 56 patients (8.9%) in the edoxaban group and in 6 of 55 patients (10.9%) in the dalteparin group (risk difference, -2.0%; 95% CI, -13.1% to 9.1%, Figure 1E ). In this period, recurrent VTE occurred in 2 patients (3.6%) treated with edoxaban and in 4 (7.2%) treated with dalteparin (risk difference, -3.7%; 95% CI, -13.9% to 6.5%, Supplementary Figure 2 ). On-treatment major bleeding occurred in one patient (1.8%) in the edoxaban group and 2 (3.6%) in the dalteparin group (risk difference, -1.9%; 95% CI, -9.7% to 6.0%, Supplementary Figure 3) . The sensitivity analysis restricted to the first 6 months is shown in Table 2 . Outcomes for individual types of hematological malignancy for the 6-and 12-month period are presented in Supplementary Tables 4 and 5 , respectively.
Gynecological cancer
Of the 111 patients with gynecological cancer, 52 (46.9%) had ovarian cancer, 37 (33.3%) endometrial cancer, 14 (12.6%) cervical cancer, 5 (4.5%) vulvar cancer, and 2 (1.8%) other types of gynecological cancer. The mean age was 65.2 years and distant metastasis was present in 66.7% of patients.
During the 12 month-study period, the primary outcome occurred in 5 (10.4%) and 11 (17.4%) patients treated with edoxaban and dalteparin, respectively (risk difference, -7.0%; 95% CI, -19.8% to 5.7%; Table 2; Figure 1F ). Recurrent VTE occurred in 3 (6.3%) treated with edoxaban and in 9 (14.3%) treated with dalteparin (risk difference, -8.0%; 95% CI, -21.0% to 4.8%, Supplementary Figure  2 ). On-treatment major bleeding occurred in 2 (4.2%) and 2 (3.2%) patients treated with edoxaban and dalteparin, respectively (risk difference, 0.1%; 95% CI, -7.1% to 9.1%, Supplementary Figure 3 ). The location of the two major bleeding events was vaginal in the edoxaban group. In the dalteparin group, one major bleeding event occurred in the lower gastrointestinal tract, and the other major bleeding event occurred in the peritoneum. 208 Chapter 10 The sensitivity analysis of events that occurred during the first 6-months showed comparable results ( Table 2) . Outcomes for individual types of gynecological cancer for the 6-and 12-month period are presented in Supplementary Tables  4 and 5 , respectively.
DISCUSSION
This analysis focused on several groups of patients with prevalent cancer types and VTE enrolled in the Hokusai VTE Cancer study. It extends the main findings of the previously reported trial by providing new subgroups based on adjudicated cancer diagnoses, including those with gastrointestinal, lung, urogenital, breast, hematological, and gynecological cancer. Additionally, we now present outcomes for both the 6-and 12-month follow-up period as well as absolute risk differences for these groups. Since the event numbers in some of the subgroups were modest, the results are primarily useful for hypothesisgeneration and should be interpreted with caution. Nonetheless, the findings presented here can be reassuring for clinicians intending to treat patients from these important cancer groups with edoxaban.
Out of the total study population, approximately one third had gastrointestinal cancer at entry. In this group, the benefit-risk trade-off requires careful evaluation because edoxaban was associated with an absolute 9.2% increase in major bleeding compared with dalteparin during the 12-month study period. The absolute risk of recurrent VTE was 3.9% numerically lower with edoxaban. Therefore, the choice of anticoagulant therapy in patients with gastrointestinal cancers needs to account for the competing risks of major bleeding and recurrent VTE, the observation that the frequency of major bleeds with a severe clinical presentation with edoxaban was roughly similar to that with dalteparin, and patient preference for the route of anticoagulant administration [9, 12, 13] .
The Hokusai VTE Cancer study included 138 patients (13.2%) with urogenital cancer of whom 56 (41%) had renal or bladder cancer. The benefit-risk tradeoff with edoxaban and dalteparin in this subgroup was consistent with that in the overall study ( Table 2) . Recent consensus guidance suggests LMWH over a direct oral anticoagulant for treatment of VTE in patients with urothelial or genitourinary cancer based on a perceived higher bleeding risk in the urogenital tract with direct oral anticoagulants [14, 15] . Of the 28 patients with bladder or renal cancer assigned to edoxaban, only one of experienced a major bleeding while on-treatment (3.6%; Supplementary Table 3 ), although this result should be interpreted cautiously given the low number.
Among patients with lung cancer (14.5%), the benefit-risk trade-off with edoxaban and dalteparin was consistent with that in the overall study; edoxaban was associated with numerically higher risk of major bleeding, but fewer recurrent VTE events. None of the patients with lung cancer developed a pulmonary bleeding. In patients with breast or gynecological cancer, edoxaban was associated with a numerically lower risk of recurrent VTE or major bleeding. These observations render oral edoxaban an attractive alternative to dalteparin for treatment of patients with lung, breast, or gynecological cancer.
A total of 111 patients (11% of the total population) with hematological malignancies were included, most of whom had multiple myeloma or lymphoma (76%). Although the number of such patients is modest, this is the largest prospective anticoagulant comparison study evaluating the risk of recurrent VTE and bleeding in patients with hematological malignancies. The benefit-risk profile with edoxaban and dalteparin in this group of patients was consistent with that in the overall study [9] .
A strength of this study is the complete follow-up of nearly all randomized patients, and similar adherence in both treatment groups [9] . For the present analysis, adjudicated cancer diagnoses were used based on detailed pathology reports, whereas the subgroups analysis in the main study were based on unconfirmed data provided by the study sites. For example, this resulted in reclassification of 60 patients with gastrointestinal cancer, making the present analysis more informative for oncologists.
Since placebo injections were considered inappropriate, the study design was not double blind. To mitigate this potential limitation, an independent committee unaware of treatment allocation adjudicated all outcomes. The difference in treatment durations with the two regimens may complicate the interpretation of the study findings. However, the analyses conducted at 6 months, which was the minimum treatment duration required, yielded comparable results to those performed over the entire 12-month study period in each of the three subgroups. The Hokusai VTE Cancer study used a primary combined outcome because the impact of recurrent VTE and major bleeding was considered to be comparable from an oncological and patient perspective. Low-to-moderate quality evidence of non-adjudicated data indicates that the case-fatality rate associated with recurrent cancer-associated VTE may be higher than for major bleeding, which could influence the choice of anticoagulant therapy [18] . Therefore, separate time-to-event curves for recurrent VTE and major bleeding in the different subgroups were provided in Supplementary Figure 2 only depend on the trade-off between recurrent VTE and major bleeding, but also on other factors that including potential drug-drug interactions with edoxaban, impaired renal function, and thrombocytopenia.
In conclusion, oral edoxaban is an attractive alternative to subcutaneous dalteparin for the treatment of the majority of patients with cancer-associated VTE, including those with urogenital, lung, breast, hematological, and gynecological cancer. Additional considerations, including patient preference, are required for the use of edoxaban in patients with gastrointestinal cancer given the increased risk of major bleeding.
